menu
    • menu
    [{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"IFx-Hu2.0","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TuHURA Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TuHURA Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Moffitt Cancer Center | University of Southern California | Dana-Farber Cancer Institute | Huntsman Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"IFx-Hu2.0","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TuHURA Biosciences \/ Moffitt Cancer Center | University of Southern California | Dana-Farber Cancer Institute | Huntsman Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"TuHURA Biosciences \/ Moffitt Cancer Center | University of Southern California | Dana-Farber Cancer Institute | Huntsman Cancer Institute"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IFx-Hu2.0","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TuHURA Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TuHURA Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"IFx-Hu2.0","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TuHURA Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TuHURA Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IFx-Hu2.0","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TuHURA Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TuHURA Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"IFx-Hu2.0","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TuHURA Biosciences \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"TuHURA Biosciences \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Kintara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TuHURA Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"TuHURA Biosciences \/ TuHURA Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"TuHURA Biosciences \/ TuHURA Biosciences"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"CohBar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TuHURA Biosciences \/ CohBar","highestDevelopmentStatusID":"9","companyTruncated":"TuHURA Biosciences \/ CohBar"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Kintara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TuHURA Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"TuHURA Biosciences \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"TuHURA Biosciences \/ TuHURA Biosciences"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TuHURA Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"TuHURA Biosciences \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"TuHURA Biosciences \/ TuHURA Biosciences"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Merger","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TuHURA Biosciences \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"TuHURA Biosciences \/ TuHURA Biosciences"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Merger","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TuHURA Biosciences \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"TuHURA Biosciences \/ TuHURA Biosciences"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Merger","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TuHURA Biosciences \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"TuHURA Biosciences \/ TuHURA Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by TuHURA Biosciences

    Menu

    TuHURA Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Kineta

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            TuHURA Biosciences Completes Acquisition of Kineta

                            Details : Under the merger agreement, the combined companies will jointly advance the clinical pipeline, including KVA12123, which is currently being evaluated for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 30, 2025

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Kineta

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Kineta

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            TuHURA and Kineta Stockholders Approve Merger and Related Proposals

                            Details : Under the merger agreement, the combined companies will jointly advance the clinical pipeline, including KVA12123, which is currently being evaluated for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 23, 2025

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Kineta

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IFx-Hu2.0

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants ...

                            Details : IFx-Hu2.0 is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Merkel Cell.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 27, 2025

                            Lead Product(s) : IFx-Hu2.0

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IFx-Hu2.0

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

                            Details : IFx-Hu2.0 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Merkel Cell.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 23, 2025

                            Lead Product(s) : IFx-Hu2.0

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Kineta

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

                            Details : Under the merger agreement, TuHURA will acquire Kineta, including the rights to Kineta’s novel KVA12123 antibody, which is being evaluated for the treatment of cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 12, 2024

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Kineta

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Kineta

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kineta Extends TuHURA Biosciences Deal for KVA12123 VISTA Antibody in Phase 1

                            Details : KVA12123 is a novel VISTA blocking monoclonal antibody being evaluated in a Phase 1/Phase 2 clinical trial for patients with advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 02, 2024

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Kineta

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Kintara Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kineta Signs Exclusivity Agreement for VISTA Blocking Antibody with TuHURA Biosciences

                            Details : Under the agreement, Kineta has granted TuHURA an exclusive right to acquire Kineta’s worldwide patents rights and development program related to KVA12123 for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            July 08, 2024

                            Lead Product(s) : KVA12123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Kintara Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IFx-Hu2.0,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Kintara Therapeutics

                            Deal Size : $31.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

                            Details : Through the merger, TuHURA will focus on the clinical development of the IFx-Hu2.0 (IFx-2.0) vaccine in combination with Keytruda for the treatment of advanced Merkel cell carcinoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 03, 2024

                            Lead Product(s) : IFx-Hu2.0,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Kintara Therapeutics

                            Deal Size : $31.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IFx-Hu2.0,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : CohBar

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stag...

                            Details : The combined company will focus on advancing Morphogenesis’ lead personalized cancer vaccine, IFx-Hu2.0, designed to prime the activation of the immune system to target and attack tumor cells by making them look like bacteria.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : IFx-Hu2.0,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : CohBar

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            TuHURA Biosciences

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IFx-Hu2.0

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

                            Details : IFx-Hu2.0 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Skin Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 14, 2021

                            Lead Product(s) : IFx-Hu2.0

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth